Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sezary syndrome.

ABSTRACT:

Background

Cutaneous T-cell lymphomas (CTCL) are rare types of non-Hodgkin lymphoma, which present in skin. Mycosis fungoides (MF) and Sézary syndrome (SS) are subtypes which make up two-thirds of all CTCL cases. The phase 3 MAVORIC study (NCT01728805) compared mogamulizumab to vorinostat in MF and SS patients, with post hoc data showing a trend for higher efficacy in mogamulizumab-treated patients as baseline blood tumour burden increases.

Objectives

The aim of this study was to use updated post hoc analyses in order to examine the efficacy of mogamulizumab and vorinostat in MF patients when stratified by baseline blood involvement and to determine what factors affect time-to-global and time-to-skin response to inform clinical follow-up.

Methods

Post hoc analyses wer

SUBMITTER: Beylot-Barry M 

PROVIDER: S-EPMC10087984 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature